Calmare Therapeutics Incorporated (OTCQB: CTTC)
, the Calmare Pain Mitigation Therapy™ company, researches, develops and commercializes chronic, neuropathic pain and wound affliction devices. Our flagship medical device - the Calmare® Pain Therapy Device - is the world's only non-invasive and non-addictive modality that can successfully treat chronic, neuropathic pain.
The Company holds a U.S. Food & Drug Administration 510k clearance designation (K081255) on its flagship device, which grants it the exclusive right to sell, market, research and develop the medical device in the United States. Calmare Devices are commercially sold to medical practices throughout the world. They are also found in U.S. military hospitals, clinics and on installations via CTI's General Services Administration (GSA) military contract (V797P-4300B).
Headquartered in Fairfield, Connecticut in 1968, more than 6,000 chronic pain patients have been successfully treated with Calmare Pain Mitigation Therapy™ since the first Calmare chronic pain treatment was administered in 2007.
CTI has a world class team of professionals with diverse technical, legal, intellectual property, marketing and business experience.